Fragment-based drug discovery requires throughput to process large numbers of samples and the sensitivity for low molecular weight analytes and weak affinity interactions. In this webinar, Dr. Aman Singh will present the results of a 5000-compound fragment screening efforts to find alternative Caseinolytic protease P (ClpP) binders using the Pall ForteBio Pioneer FE system. ClpP represents an important emerging target for the treatment of chronic bacterial infections. Antibiotic acyldepsipeptides (ADEPs) specifically target the ClpP allosteric activation domain resulting in deregulated activation of ClpP and self-digestion. A retrospective analysis of the success of SPR, TSA, FP assays against this complex protein-protein interaction site target will also be presented.
The Pioneer FE system offers label-free identification of fragment candidates on large numbers of samples and obtains reliable affinity (KD) and kinetic (ka, kd) data directly from the primary screen. The webinar will also provide an overview of the Pioneer platform technology and its application in a real-life discovery workflow.
Aman Singh, PhD, Post-doctoral Researcher, St. Jude Children’s Research Hospital
Aaron Martin, Applications Manager, Pall ForteBio
Thursday, May 25, 2017
8:00 AM Pacific Daylight Time | 5:00 PM Central European Time